Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evotec SE Investor Presentation 2011

Jun 10, 2011

151_ip_2011-06-10_3d5a4252-966d-467d-b2b6-8f9dcb48f454.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Building innovative drug discovery alliances

Best in Class Drug Discovery - Evotec Company Pres entation

Evotec AG , Jefferies 2011 Global Healthcare Conference , 6 - 9 June 2011

Forward-looking s statements

Information set forth in this presen forward-looking statements, which invo risks and uncertainties ncertainties. The forward forward-lo contained herein represent the judgemen the date of this report. Such forward-lo are neither promises nor guarantees, bu variety of risks and uncertainties, man ntation containsolve a number ofoking statements nt of Evotec as ofooking statements ut are subject to a ny of which are

beyond our control, and which could cause actual results to differ materially from those contemplated in these forward looking statements We e pressl disclaim an forward-lookingstatements. expressly any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Agenda

• Strategic background & & Business model

  • • Discovery alliances & De evelopment partnerships
  • • Financial strategy & Out tlook

The external innovvation opportunity

Key growth factors

Building drug hun ting alliances

Solutions to accelerate innnovation

  • Strong track record after >1 Hamburg years drug discovery histor 15 ry

  • 100 lead series

•

  • 30 preclinical candidate es

  • 20 clinical compounds Oxford

  • • Comprehensive integrated approach in major therapeu areas
  • • Innovative disease biology new drug targets for
  • Th t i iti t• Three recent acquisitions to expand into metabolics, oncology and compound tmanagement1) ots
  • •More than 500 top-scientist

Our valueproposition

High quality drug discovery development solutions to ourpartners

Building best in cl infrastructuresass drug y discovery

Our business model

Best-in-class drug g discovery infrastructures

Why people work with us

Compound manag our alliancesgement as an integrated solution in

Recent Acquisition: Role o of compound management in Evotec's value chain

Best practice operations

Agenda

  • • Strategic background & Business model
  • • Discovery alliances & Development partnerships
  • • Financial strategy & Out tlook

Well balanced por rtfolio of top-class partners

Selected drug discovery al lliances (1/2)

P
t
a
r
n
e
r
s		 F
o
c
s
a
r
e
a
u		 U
i
d
f
p
s
e
o
r
E
t
o
e
c
v		 D
i
i
t
e
s
c
r
p
o
n
O
l
i
n
c
o
o
g
y,
p
a
n
,
i
f
l
i
t
n
a
m
m
a
o
n		 +
+
+		 P
f
b
d
l
i-
l
t
t
t
t
e
r
o
r
m
a
n
c
e
a
s
e
m
u
a
r
g
e
o
n
g
e
r
m
-
-
,
l
l
i
S
i
i
f
i
i
l
d
l
i
t
t
t
a
a
n
c
e
g
n
c
a
n
m
e
s
o
n
e
s
a
n
r
o
y
a
e
s
C
S
N
H
t
i
t
u
n
n
g
o
n
,
d
i
s
e
a
s
e		 +
+		 f
f
L
t
l
l
i
d
t
h
i
h
t
o
n
g
e
r
m
a
a
n
c
e
o
c
u
s
e
o
n
e
g
-
,
i
H
i
d
i
t
t
t
a
g
a
n
s
u
n
n
g
o
n
s
e
a
s
e
C
N
S
i
p
a
n
,
,
h
t
o
e
r
s		 +
+		 L
l
l
i
f
d
l
i
l
t
t
o
n
g
e
r
m
a
a
n
c
e
o
c
u
s
e
o
n
m
u
p
e
-
,
t
t
a
r
g
e
s
C
N
S
i
p
a
n
,		 +
+		 P
f
b
d
l
l
l
i
t
e
r
o
r
m
a
n
c
e
a
s
e
o
n
g
e
r
m
a
a
n
c
e
-
-
,
,
f
d
i
S
i
i
f
i
t
i
l
t
d
o
c
s
e
o
n
p
a
n
g
n
c
a
n
m
e
s
o
n
e
s
a
n
u
l
t
i
r
o
a
e
s
y
V
i
a
r
o
s
u		 +
+		 f
P
b
d
l
t
i-
t
t
l
t
e
r
o
r
m
a
n
c
e
a
s
e
m
a
r
g
e
o
n
g
e
r
m
u
-
-
,
S
f
l
l
i
i
i
i
t
i
l
t
d
l
t
i
a
a
n
c
e
g
n
c
a
n
m
e
s
o
n
e
s
a
n
r
o
y
a
e
s

Significant milesto

S
i
i
f
i
i
l
i
d
i
h
i
k
t
t
t
t
g
n
c
a
n
m
e
s
o
o
n
e
p
s
e
o
r
s
u
w
u
l
d
d
d
l
l
l
(
/
)
S
i
i
2
2
t
g
e
e
c
e
r
u
s
c
o
v
e
r
y
a
a
n
c
e
s
i
f
U
d
p
s
e
o
r
M
t
b
l
i
e
a
o
c
s
,
i
l
i
i
t
i
n
s
u
n
s
e
n
s
z
e
r		 +
+
+
+		 D
i
b
t
b
i
t
d
t
b
l
i
d
a
e
e
s
o
e
s
y
a
n
m
e
a
o
c
s
y
n
r
o
m
e
,
R
h
f
d
i
€
7
f
t,
e
s
e
a
r
c
n
n
g
m
p
r
o
n
u
u
,
€
2
3
0
i
i
l
l
l
i
t
t
t
>
m
m
m
e
e
s
s
o
o
n
n
e
e
s
s
r
o
a
e
s
y
,
B
C
l
l
h
l
t
t
e
a
e
e
c
n
o
o
g
y
(
b
i
l
i
l
)
o
o
g
c
a
s		 +
+
+
+		 T
1
d
2
d
i
b
i
b
l
l
t
t
t
t
p
e
a
n
a
e
e
s
a
r
g
e
n
g
e
a
c
e
y
,
m
a
s
s
f
f
€
f
f
R
h
d
d
i
i
5
t
t,
e
s
e
a
r
c
u
u
n
n
n
n
g
g
m
u
u
p
p
r
r
o
o
n
n
,
€
2
0
i
l
l
i
5
t
t
>
m
m
e
s
o
n
e
s
r
o
y
a
e
s
,
A
i
n
e
m
a		 +
+		 P
f
b
d
l
l
i
f
d
e
r
o
r
m
a
n
c
e
a
s
e
a
a
n
c
e
o
c
u
s
e
o
n
-
,
i
t
t
a
n
e
m
a
a
r
g
e
s
V
i
(
l
a
r
o
u
s
a
s
o
h
h
K
i
d
t
r
o
g
n
a
o
a
n
u
x
C
d
F
o
m
p
o
n
o
c
s
u
u
,
I
I
)
)
n
n
c
c		 V
i
a
r
o
u
s		 M
l
i-
l
l
l
i
t
t
t
t
u
a
r
g
e
o
n
g
e
r
m
a
a
n
c
e
s
-

Reduction of own strategy clinical risk-exp y osure is key for

Portfolio of product develo opment partnerships

i
i
I
d
t
n
c
a
o
n		 P
t
a
r
n
e
r		 S
t
t
a
s
u		 i
U
d
p
s
e
f
E
t
o
r
o
e
c
v		 i
N
l
t
t
e
m
e
s
o
n
e
x
)
1
T
1
d
i
b
t
y
p
e
a
e
e
s		 P
h
I
I
I
a
s
e		 +
+
+		 P
h
I
I
I
d
t
2
0
1
2
a
s
e
a
a
T
i
t
t
t
t
r
e
a
m
e
n
r
e
s
s
a
n
d
i
(
T
R
D
)
e
p
r
e
s
s
o
n		 o
p
e
n		 P
h
I
/
I
I
a
s
e		 +
+
+		 o
p
e
n
2
)
I
i
n
s
o
m
n
a		 P
h
I
I
a
s
e		 +
+		 2
2
0
1
P
h
I
I
b
d
t
a
s
e
a
a
P
i
a
n		 P
h
I
a
s
e		 +
+		 P
h
I
a
s
e
I
f
l
i
t
n
a
m
m
a
o
n		 P
h
I
/
a
s
e
l
i
i
l
p
r
e
c
n
c
a
a		 +
+
+		 F
i
P
h
I
d
t
t
r
s
a
s
e
s
o
p
p
e
,
b
k-
i
i
t
a
c
u
p
n
p
r
e
p
a
r
a
o
n
)
3
C
S
N
P
i
U
I,
t
h
a
n
o
e
r
s
;
,		 P
l
i
i
l
r
e
c
n
c
a
a		 +
+
+		 /
P
h
I
t
i
a
s
e
p
a
r
n
e
r
n
g

DiaPep277 – Type 1 diabetes

Example: Andromeda Bio tech/Teva Pharmaceuticals

P
t
a
r
n
e
r		 S
D
l
t
t
e
v
e
o
p
m
e
n
a
g
e		 I
d
i
i
t
n
c
a
o
n		 T
t
a
r
g
e
P
h
I
I
I
a
s
e		 i
T
1
D
b
t
y
p
e
a
e
e
s		 H
6
0
s
p
A
l
t
h
t
i
t
n
o
v
e
e
r
a
p
e
u
c
r
•
d
i
b
1
t
i
t
t
p
e
a
e
e
s
y
p
a
e
S
h
i
i
d
d
t
t
t
n
e
c
p
e
p
e
y
−
P
t
t
b
t
l
l
r
o
e
c
s
e
a
c
e
s
−
d
i
t
t
e
s
r
c
o
n
s
u		 d
o
o
s
e
6
6
0
t
t
d
e
(
%
f
P
t
t
i
l
k
t
5
1
0
d
i
b
t
i
h
T
I
o
e
n
a
m
a
r
e
o
a
e
c
s
a
v
e
y
p
e
e
•
-
d
i
b
)
t
a
e
e
s
/
A
d
d
T
i
k
i
l
t
t
t
t
t
t
n
r
o
m
e
a
e
v
a
e
s
m
a
e
s
m
a
r
e
p
o
e
n
a
a
m
o
r
e
−
\$
t
h
5
0
0
M
a
n
P
h
I
I
I
d
(
D
I
A
A
I
D
1
)
d
2
0
1
2
t
t
a
s
e
a
a
e
x
p
e
c
e
-
−
D
i
P
2
7
7
a
e
p

Long time experts in CNS

CNS alliances

EVT 1001)

  • • Status: Phase I/II (first Phase II terminated)
  • • EVT 101 /103 are high affinity, selective antago D-aspartate (NMDA) receptor subtypes contain subunitonists of N-methylning the NR2B
  • • Potential indications: Treatment Resistant Depr ression, Pain, AD

Other CNS alliances

  • •Status: Pre-clinical
  • CHDI M lti lli t fi d t t • – Multi-year alliance to find new treatmen Huntington's disease using integrated discovery collaboration extended twice since 2006nt f sor y offering;
  • • Others: − ONO Pharmaceutical – Multi-target , multi-year alliance year
  • Genentech – Multi-target, multi-year r alliance
  • Merck KGaA – Neurological target, m multi-year alliance

Next value points:

• Partnering and or milestones in other programs

1) EVT 101 /103 are high affinity, selective antagonists of N activated form of the receptor (activity-dependent); the N-methyl-D-aspartate (NMDA) receptor subtypes containing the NR2B subunit; they bind preferentially to the ey modulate channel activity by inhibiting channel opening probability

Broad franchise inn pain and inflammation

Pain & inflammation alliannces

Pain & Inflammation alliance

  • • Partnership with Boehringer Ingelheim for e.g neuropathic pain g. treatment of
  • • Si ifi t b f th t t i Significant number of other targets in pre-cli i nc cal t s
  • • Short-to-mid-term milestone potential, single-d royalties igit product

Other Pain & Inflammation alliances

  • • Status: Pre clinical Pre-clinical
  • • Others:
  • Genentech – Multi-target, multi-year alliance e
  • Pfizer Alliance focused on VR1 antagonist
  • Novartis Alliance focused on pain target

age Next value points:

  • •Clinical progress
  • • Nomination of clinical candidates
  • • Pre-clinical milestones

World leading mas oncology field eve ss spectrometry to open Oncology p yp en broaderalliances

Oncology alliances

Oncology alliance

  • • Optimal use of Boehringer Ingelheim target a know-how with Evotec science and technologie and biology es
  • • Incentives based on success and long-term pro minimum of four years; minimum € 15m base c sig y yp nificant milestones and royalty upside oduct upside; contract;

Other oncology alliances (through Kinaxo)

  • AstraZeneca Evotec will apply its technolo – its support oncology program ogy platform to • Leverage of
  • Daiichi Sankyo long-term partnership in c cancerresearch
  • Janssen Ph ti l Pharmaceutical– E t vo ec t l o appy and servicesy it t h l its technology

Next value points:

  • • Nomination of clinical candidates
  • • Pre-clinical milestones
  • technologies in new alliances

A world leading fr regenerative medi anchise in beta cell biology and icine

Evotec´s CURE BETA fr anchise

Regenerative med icine at Evotec

Beta cell regeneration and dbeyond

B
l
l
t
e
a
c
e
i
i
t
r
e
g
e
n
e
r
a
o
n
v
a
l
l
l
l
s
m
a
m
o
e
c
e
s
u		 D
i
b
i
d
b
l
f
b
b
l
l
t
t
a
e
e
s
s
c
a
s
e
o
s
s
o
e
a
c
e
s
u
y
•
C
t
d
d
t
t
b
b
t
l
l
l
u
r
r
e
n
r
u
g
s
o
n
o
p
r
e
v
e
n
e
a
c
e
o
s
s
•
A
h
T
b
l
l
i
i
l
l
i
l
b
l
l
l
l
l
t
t
t
p
p
r
o
a
c
a
r
g
e
e
a
c
e
r
e
e
g
e
n
e
r
a
o
n
a
o
r
a
a
a
a
e
s
m
a
m
o
e
c
e
s
:
v
y
v
u
•
C
i
i
h
k
d
r
o
n
c
n
e
y
i
(
C
)
d
K
D
s
e
a
s
e		 C
K
D
h
h
i
h
i
i
d
l
i
d
t
t
t
t
t
t
a
s
g
n
c
e
n
c
e
m
o
r
a
a
y
a
n
r
e
a
m
e
n
c
o
s
s
•
,
D
i
l
i
i
h
l
i
f
i
i
h
d
l
d
i
(
E
S
R
D
)
t
t
t
t
t
t
t
t
t
a
y
s
s
s
e
o
n
y
r
e
a
m
e
n
o
o
p
o
n
o
r
p
a
e
n
s
w
e
n
s
a
g
e
r
e
n
a
s
e
a
s
e
•
/
A
h
P
d
i
i
t
t
t
t
t
p
p
p
p
r
o
a
c
o
o
c
y
y
e
p
p
r
o
e
c
o
n
r
e
g
e
n
e
r
a
o
n
:
•
M
l
u
s
c
e
i
t
r
e
g
e
n
e
r
a
o
n
(
h
f
i
l
)
t
e
g
e
a
r
a
r
e
u		 L
d
i
f
b
i
d
i
d
l
i
l
d
i
d
t
t
t
e
a
n
g
c
a
s
e
o
m
o
r
a
n
m
o
r
a
o
r
e
u
y
y
w
w
•
L
i
i
t
d
t
t
t
t
i
m
e
r
e
a
m
e
n
o
p
o
n
s
•
A
h
R
i
f
t
t
p
p
r
o
a
c
e
g
e
n
e
r
a
o
n
o
m
m
o
c
e
s
:
y
y
•
i
i
N
N
d
d
t
e
r
o
e
g
e
n
e
r
a
e
u
v
i
d
s
e
a
s
e
s		 H
i
d
i
A
D
P
D
A
A
L
S
t
t
u
n
n
g
o
n
s
e
a
s
e
•
,
,
,
L
i
i
d
i
t
t
t
t
t
m
e
r
e
a
m
e
n
o
p
o
n
s
•
S
f
f
A
h
l
l
b
d
i
d
i
d
i
i
t
t
t
p
p
r
o
a
c
e
m
c
e
a
s
e
s
s
c
r
e
e
n
n
g
o
r
s
e
a
s
e
m
o
y
n
g
a
r
g
e
s
:
•

Agenda

  • • Strategic background & Business model
  • • Discovery alliances & De evelopment partnerships
  • • Financial strategy & O utlook

Go for Growth !

Strategy overview

INNOVATE

Strong top-line gro owth

Key financials FY 2010: Co ondensed profit & loss statement (IFRS)

in €m

A
l
2
0
0
9
t
c
a
u		 A
l
2
0
0
1
0
t
c
a
u		 %
s
v
A
A
l
l
0
9
t
t
c
a
u
R
e
e
n
e
s
v
u		 4
2
7		 3
5
5		 2
9
%
+
G
i
i
r
o
s
s
m
a
r
g
n		 4
3
%.
2		 4
4
%.
1		 0
%.
9
t
+
-p
s
&
R
D
e
x
p
e
n
s
e
s
•		 2
0
9		 6
1		 %
7
1
-		 i
O
t
p
e
r
a
n
g
i
d
t
n
c
o
m
e
a
n
n
e
S
G
&
A
e
x
p
e
n
s
e
s
•		 1
6
7.		 1
1
6
6
0
0		 %
%
4
4
-		 i
n
c
o
m
e
A
i
i
&
i
i
t
t
t
m
o
r
a
o
n
m
p
a
r
m
e
n
z
•		 1
8
3		 0
7		 i
i
f
i
l
t
s
g
n
c
a
n
y
i
d
m
p
r
o
v
e
R
i
i
t
t
t
e
s
r
c
r
n
g
e
p
e
n
s
e
s
u
u
x
•		 4
8.		 0
0
0
0
O
t
h
t
i
e
r
o
p
e
r
a
n
g
e
x
p
e
n
s
e
s
•		 0
1
-		 0
1
-
O
O
i
i
i
i
(
(
l
l
)
)
t
t
p
e
r
a
n
g
n
c
o
m
e
o
s
s		 (
)
4
2
3		 1
7.
+		 1
0
4
%
+
(
)
N
i
l
t
e
n
c
o
m
e
o
s
s		 (
)
4
5
5		 3
0
+		 1
0
%
7
+

Accelerated path t to sustainability

2010 - Key figures overvie ew

in € m

  • 21 1) Including impairment and restructuring expenses of € 2 27.7m
  • 2) Including impairment and restructuring expenses of € 2 22.7m

3) Net income before extraordinary effects

Strong outlook for r 2011

Discovery alliance order b book1) overview – Status April 2011

in € m

Strong operationa al guidance for 2011

Operational business over rview

i
€
n
m
Q
1
2
0
1
0		 Q
1
2
0
1
1		 ∆
Q
1
Q
1
–		 F
Y
G
i
d
u
a
n
c
e
2
0
1
1		 F
Y
2
0
1
0
R
e
e
n
e
s
v
u		 9
8		 1
5
1		 5
4
%
+		 6
8
7
0
-		 5
5
3
O
i
i
t
p
e
r
a
n
g
n
c
o
m
e
(
l
)
o
s
s		 (
1
)
5		 (
)
0
8		 5
4
%
+		 I
d
m
p
r
o
v
e
2
0
1
0
o
v
e
r		 1
7
(
)
N
i
l
t
e
n
c
o
m
e
o
s
s		 (
1
2
)		 (
)
0
4		 6
9
%
+		 I
d
m
p
r
o
v
e
2
0
1
0
o
v
e
r		 3
0
U
d
R
&
D
t
n
p
a
r
n
e
r
e
e
p
e
n
s
e
s
x		 (
1
)
7		 (
)
2
3		 3
3
%
+		 1
0
a
p
p
r
o
x		 6
L
i
i
d
i
i
d
t
t
q
u
y
a
p
e
r
o
d
e
n		 6
6
8		 6
8
7		 3
%
+		 )
1
5
5		 0
7

Global reach for g lobal projects

Ca. 580 Evotec employees s worldwide

Expansion of team m committed to growth

Management & sharehold der structure

Strong news flow to come

Outlook and next steps fo or 2011 ff

Key milestones for 2011

G
d
i
r
o
s
c
o
e
r
w
v
y		 •
l
l
i
b
i
l
d
a
a
n
c
e
s
u
,		 •
1
j
j
i
i
i
t
t
o
n
n
n
o
a
o
n
v		 •
l
l
i
a
a
n
c
e
s		 •
  • • Build at least two signific cant new integrated technology/disease alliances
  • • Deliver significant and a accelerated preclinical/clinical milestones
  • • Show expansion succes ssof existing alliances alliances
  • • Show operational synerg gies of acquisitions

Generateoptimal pipeline progress & biotech values2

  • • At least 1 strategic deal for an early asset
  • • Generate more innovatioon upsides (e.g. Harvard cooperation, …)

Manage •and path to profitability 3

  • Prepare growth of reven innovationnues by more than 15% y-o-y into 2012ff
  • • Build profitability, withou ut infringing innovation power
  • • Keep strong strategic ca ash position

Building innovative drug discovery alliances

Your contact:

Dr Werner LanthalerChief Executive Officer

+49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax [email protected]

More from Evotec SE

Director's Dealing 2026
May 22
Major Shareholding Notification 2026
May 21
Major Shareholding Notification 2026
May 19
Major Shareholding Notification 2026
May 18
Capital/Financing Update 2026
May 12
AGM Information 2026
May 7
Interim / Quarterly Report 2026
May 6
Interim / Quarterly Report 2026
May 6
Director's Dealing 2026
May 5
Major Shareholding Notification 2026
May 5
View all filings →